Business and Finance

This serialization system represents a business imperative that yields significant competitive advantages.

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with short-term financial returns.

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment strategies in high unmet need areas.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day delivery.

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, shares the key factors that he believes are propelling a continued rise in projected R&D ROI.

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

The President plans to sign an executive order on Monday morning to enforce the trade clause.

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications.

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.

A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.

How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.

The parties aim to create an end-to-end digital thread that links research data all the way through to life sciences manufacturing.

In a move meant to encourage domestic production, the president’s executive order features a 10% baseline tax, expected to take effect April 9.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a month, while Lilly also sells the GLP-1 via its LillyDirect platform.

CRYOPDP—centered around clinical trials, biopharma, and cell and gene therapies—augments DHL’s specialty pharma logistics expertise.